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1.0 Thesis Overview:
Pharmaceutical companies are under increasing financial pressure to optimise
production costs, due to a growing number of products coming off patent, research
and development costs increasing exponentially and the difficulty of bringing
genuinely innovative products to market. Generic drug manufacturers are not exempt
from these pressures; costs must be driven down by all drug manufacturers due to the
increasingly competitive healthcare market.
The operating costs of a modern Pharmaceutical Plant run to several Million Euros
per annum. Complex process’s involving the consumption of large amounts of
energy, and hence costs, are a necessity. Any increase in the efficiency of a
manufacturing plant will be reflected in profit margins. An added benefit to this cost
reduction is the associated decrease in greenhouse gas emissions.
In this study I review the current financial threats to the Pharmaceutical industry,
examine the response of the industry to these threats and explain in detail some of
the equipment involved in manufacturing these drug products.
Furthermore I analyse and break down the energy consumption of the Research and
Development Pilot Plant at GlaxoSmithKline, Cork into its constituent parts, identify
inefficiencies and implement a project using software to reduce the costs associated
with this energy wastage.
The project specifically targets the largest contributor to the Pilot Plant’s energy
costs- Steam, and software development to reduce the buildings consumption of this
service.

I'he algorithm preselects parameters on the building Distributed Control System
(DCS) which must be met to ensure Steam is only used for the heating and cooling
of vessels via Dowtherm'^’'^ J when the reactor vessels are in use and require
temperature control. Detailed analysis is provided regarding the project process and
the impact this project has on reducing the running costs of the Pilot Plant.

1.1 Literature Review
1.2 Summary

Pharmaceutical companies have faced increasing internal and external pressures over
the last decade (Mittra et al, 2010). Their reliance on blockbuster drugs (drug
products which generate annual sales of at least $1 Billion) to maintain profits have
required an ever increasing investment in Research and Development (Paul et al,
2010).

The blockbuster model is maturing (Day et al., 2011), leaving Pharmaceutical
companies at a crossroads, either to continue pumping enormous sums of money into
research and development for replacement blockbuster drugs or to diversify into a
larger number of markets with less potential for financial returns.
These financial pressures have focused the attention of “Big Pharma'’ to address
underlying cost issues. Pharmaceutical companies were traditionally viewed as a
“golden goose” (Smith, 1980), with the enormous costs associated with the
discovery and manufacture of blockbuster drugs being viewed as a necessity
(Cuatrecasas, 2006).
In response to dwindling profits Pharmaceutical companies are aggressively
lowering manufacturing costs by outsourcing raw materials and intermediate
products and streamlining processes (Edged et al., 2008).
The additional benefit of Pharmaceutical companies lowering energy costs is the
associated reduction in their respective Carbon Footprints. Indeed, the key players in
the field have given firm commitments regarding lowering their Carbon Footprints
(GSK Annual Corporate Responsibility Report 2011, Pfizer Green Journey Policy

Report 2010).Herein, I review the current difficulties facing the Pharmaceutical
sector, with a specific focus on the cost implications, both economic and
environmental associated with these challenges.

1.3 Economic Costs
1.3.1 The Patent Cliff
Perhaps one of the most significant and pressing issues facing today’s
pharmaceutical sector is the so-called

'‘patent-cliff’ (Holmes, 2012), the

phenomenon of blockbuster drugs coming off patent and facing competition from
cheaper generic versions of the products.
As illustrated in table 1, several blockbuster drugs patents either already have, or are
facing patent expiry in the next two to three years:
Table 1. Blockbuster Drugs facing patent expiry
Company

Product

US Sales $

Approval

Expiry

Squibb

Plavix

6.8 Billion

Nov, 1997

May, 2012

AstraZeneca

Nexium

6.2 Billion

Mar, 2000

May, 2014

Squibb

Abilify

5.2 Billion

Nov, 2002

Oct, 2014

GlaxoSmithKline

Advair

4.6 Billion

Aug, 2000

Mar, 2012

AstraZeneca

Seroquel

4.6 Billion

Sep, 1997

Sep,2011

Merck

Singulair

4.6 Billion

Feb, 1998

Aug, 2012.

AstraZeneca

Crestor

4.4 Billion

Dec, 1996

Nov, 2016

Eli Lilly

Cymbalta

3.7 Billion

Aug, 2004

Jun, 2013

Abbott

Humira

3.5 Billion

Dec, 1998

Dec, 2016

Bristol-Myers

Bristol-Myers

Modified from- The 10 Best Selling Prescription Drugs in the United States, Max Niesen

1.3.2 Lipitor
As a specific example the drug Lipitor {Atorvastatin Calcium) belonging to a new
class of cholesterol lowering medication called statins, provides us with a prime
illustration of the pressures facing Pharmaceutical companies within the last decade.
Lipitor is the bestselling drug in history, with sales of $125 Billion since its launch in
1996 by Pfizer Pharmaceuticals (Lindsley, 2010). The product lost patent protection
in late 2011, with the result that Pfizer’s Lipitor US sales have declined by 70%, as
competition from generic versions (Watson Pharmaceuticals and Ranbaxy
Laboratories) have aggressively captured market share (Dimond, 2011). Pfizer
manufactures Lipitor at its production facility in Loughbeg, Cork. The direct impact
o\' Lipitor coming off patent was the reduction in the workforce at the Pfizer plant by
177 people and a 9% drop in total Irish exports as reported by the Irish Central
Statistics Office in December 2011 (Roche, 2012).

1.3.3 Research and Development Costs
Pharmaceutical companies are increasingly examining the enormous amounts of
money spent on Research and Development.
Table 2. Pharmaceutical Research and Development Cost over 5 years
(US $ Billions)
Pfizer R&D Expense Range

Merck R&D Expense Range

Minimum:

1.632

Minimum:

1.078

Maximum:

2.802

Maximum:

4.559

Average:

2.137

Average:

1.854

J&J R&D Expense Range

GSK R&D Expense Range

Minimum:

1.518

Minimum:

1.145

Maximum:

2.328

Maximum:

2.113

Average:

1.826

Average:

1.621

Modified from Form 10-K (US stock exchange annual submission) for individual companies

New financial models are being tested, with outsourcing and the buying out of
smaller companies being the most prevalent methods of attempting to stem the
flow of decreasing new products versus increasing research and development
costs. As a direct result of Pfizer slashing financial overheads, it closed its
research and development facility in Kent in 2011 with the loss of 2,400 jobs
(Inman et al, 2011). This is the same facility which discovered Pfizer’s most
famous product Viagra, with annual sales of nearly $2 Billion in 2011 (Pfizer
Annual Results, 2011).

R&D spending, $M

FDA-approved NMEs

70,000
60,000
50,000
40,000
30,000

20,000
10,000

0

Figure 1. Research and Development Costs versus New Molecular Entities
Discovered.
Bunnage M. (2011) Getting pharmaceutical R&D back on target, Nature Chemical Biology

1.4 Pharmaceutical Patents

A patent is defined as a legal device that grants inventor market exclusivity over a
new invention or medication (Gupta el al., 2010). The cost of discovering and
developing a Pharmaceutical product is estimated to be in the region of $800 Million
dollars, whereas generic medicines cost approximately two Million dollars to
develop, and quickly capture a significant portion of the market once available
(Dickson et al, 2009). Pharmaceutical companies patent their products to ensure
market exclusivity for a period of twenty years -medical patents last for twenty
years, but on average it takes four to six years from discovery to point of sale for a
product. This exclusivity is a vital incentive for companies to invest such large sums
of money in research and development.

Prior to 1984 generic companies had only a marginal effect on the profitability of
major Pharmaceutical companies. This was due to the fact that for the generic
version of an existing drug to be approved by the Federal Drug Administration (FDA
- the regulatory body for drugs in the United States), generic companies had to
conduct the same safety and efficacy tests as the original patent holders (Frank ,
2007). These preconditions made the production of generic drugs financially nonviable in the majority of cases.
The Drug Price Competition and Patent Restoration Act (1984 US “Hatch-Waxman
Act”) drastically changed the drug manufacturing landscape, facilitating the ease
with which generic companies could compete with drug patent holders. The HatchWaxman Act contained three key principals:

Generic companies that establish bioequivalence of their product and
the manufacture of same adhere to FDA guidelines do not need to
conduct safety and efficacy tests.

Generic companies can establish bioequivalence and submit for FDA
approval before a patent expires.

A process was put in place to seek resolution between patent holders
and generic drug manufacturers should disputes arise.

The third principal is especially significant as the first generic drug manufacturer to
gain FDA approval is granted an exclusive 180 day marketing period among generic
manufacturers.
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In cases where disputes arise between patent holders and generic drug manufacturers
regarding patent infringement, the dispute cannot be resolved by the FDA for a
period of 30 months or the courts make a binding decision. This situation has been
used effectively by Pharmaceutical companies in the past to curtail competition from
generic drug manufacturers Pfizer's patent on the drug Lipitor was fiercely contested
by the generic manufacturers Ranbaxy and Arrow Generics in the courts in the UK
and USA close to the patent ending, in an attempt to open the marketplace to generic
manufacturers of Lipitor (Owens, 2005).
A company wishing to make a generic version of a drug must certify one of the
following with regard to the patent owners New Drug Application (NDA):
•

The product has not been patented

•

The patent has expired

•

fhe patent will expire on a certain date

•

The patent is not infringed

1.4.1 Patent Extension Strategies
Once a company loses a patent, it signals the end of market dominance for that
product. Pharmaceutical companies have evolved several strategies to extend the
patents of their products:
•

Different Formulation (e.g. extended release-once weekly)

A patent holder can extend their patent for a product if they can:
1) Demonstrate a different formulation which is demonstrably better than the
original formulation
2) Demonstrate improved side-effects.
11

Elli Lilly successfully extended the patent for their product Prozac by reformulating
the original recipe to a once weekly sustained release format (Gupta et ai, 2010).
Bristol-Myers Squibb extended the patent for their product Glucophage by
reformulating the original recipe to a once daily dose, renamed Glucophage XR
(Kesselheim, 2007)
•

New administration route for drug

If a patent holder can develop new routes to administer a drug they ean get an
extension to an existing patent.
GlaxoSmithKline developed a new intranasal route of administration for its migraine
product Imitrex thereby extending its patent protection (Gershell et ai, 2006).
•

Enantiomers

Many drugs on the market are enantiomers (drugs consisting of two mirror-image
moleeules of the same chemical composition). Companies can isolate one of these
molecules and apply for a separate patent for this molecule.
AstraZeneca's enantiomer drug Prilosec (prescribed for heartburn) was re-patented
as Nexiiim due to the isolation of the single (S) enantiomer which exhibited greater
efficacy than Prilosec (Dwivedi et ai, 2010).
•

New uses

Companies can extend their patent of a product by demonstrating new uses for their
existing product.
Pfizer originally patented the drug Viagra (for erectile dysfunction) as Revatio,
indicated to be used for Pulmonary Arterial Hypertension (Smith, 2011).
12

•

Combining drugs

Companies which demonstrate either better efficacy or new uses by combing drugs
can extend their patent protection.
GlaxoSmithKline holds patents for Azidothymidine (AZT), Lamivudane, and
Abacavir sulfate. To extend the patent for AZT GlaxoSmithKline has combined
AZT with Lamivudane (brand name Combivir) and AZT with Lamivudane and
Abacavir

sulfate

(brand

name

Trizivir)

for

the

treatment

of

Human

Immunodeficiency Virus (HIV) infection (Wechsler, 2005).
1.5 Generic Drug Manufacturers
"Generics now account for 75 % of the prescriptions fdled in the United States, up
from about 47 % a decade ago", according to IMS Health, an industry research firm
(Singer, 2010).
1.5.1 Teva Pharmaceuticals Profile
Teva Pharmaceuticals is the world’s largest generic drug manufacturer and the tenth
largest pharmaceutical company with revenues of $19 Billion in 2011. Teva
Pharmaceuticals originated in 1901 in Israel as a distributor importing medicines.
The company grew through mergers and acquisitions in the following decades to
become the dominant player in generic drug manufacturing. Teva currently employs
approximately 46,000 people, with operations in over 60 countries. Teva products
account for 14% ($555 Million) of US prescriptions in 2011 (TEVA 2011 SEC
Filing) .The current headquarters of Teva worldwide is based at Petach Tikva in
Israel.
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leva Pharmaceuticals 2007-2011 Revenues ($ million)
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Figure 2. leva Pharmaceuticals Revenue and Profits
From leva annual report 2011

l eva is one of several generic drug manufacturers which have seen sales grown
exponentially since the enactment of the US Hatch-Waxman Act: - Mylan
Pharmaceuticals had revenues of $6.13Billion in 2011; Sandoz (owned by Novartis)
had revenues of $10.7 Billion in 2011.
The size of these companies has given them the resources and financial clout to
aggressively challenge “Big Pharma” patent claims, as well as buy out any generic
pharmaceutical manufacturers which challenge their growing dominance. Indeed
several generic manufacturers have developed their own drugs and face the same
battle as “traditional” pharmaceutical companies in aggressively staving off patent
infringements. Teva pharmaceuticals recently (Jun. 2012) won a court ruling in the
USA regarding patent infringement of its product Copaxone for the treatment of
Multiple Sclerosis (Murphy, 2012). “Big Pharma” companies have adopted practices
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to curb the profitability of generic drug manufacturers. Several large Pharmaceutical
companies have set up their own generic manufacturing subsidiaries to stifle
profitability of their generic competitors e.g. Sandoz owned by Novartis.
Table. 3. Pharmaceutical Companies and Generic Subsidiaries
Manufacturer

Generic Division

Pfizer

GenMed, Greenstone

GlaxoSmithKline

Aspen

Novartis

Sandoz

Eli Lilly

Elanco

Abbot

Abbvie

Pharmaceutical companies have also taken advantage of the Hatch-Waxman Act by
directly collaborating with a generic manufacturer to ensure that they are the first to
patent their generic product (180 days generic exclusivity) in return for a pereentage
of profits.
For example Watson Pharmaceuticals were aided by Pfizer (patent holder) to gain
the first generie patent for Lipitor in return for a percentage of profits (Jackeviciu et
r//.,2012)
1.6 Ireland and Generic Medicines
The Irish Pharmaceutical sector employs approximately 5% of manufaeturing
employment and accounts for 16% of the country’s industrial exports (2008) (Van
Egeraat, 2012). Eight of the top ten Pharmaceutical Companies have manufacturing
operations in Ireland with exports of Pharmaceutical products exceeding 19.5 Billion

15

euro’s in 2009.

The industry directly employs over 24,000 people (2010), the

majority of which are highly educated and skilled (Enterprise Ireland, 2010).
Over €85 Billion of financial support was received by Ireland in 2010 from the
EU/IMF to stabilise the country’s banking system following the crash of several
major banks. The financial injection had several conditions attached, requiring
stringent cuts to public expenditure. The Irish health sector was not immune to these
cuts, with €746 Million of savings forecast in the health sector in 2011 with an
additional €680 Million of savings forecast for the period 2012-2013 under the
National Recovery Plan (ERSI, 2012).
The budget allowance to the Health Service Executive (H.S.E.) in 2011 was just
under 13.5 Billion euro's. Irish public spending on prescription medicines exceeded
€2.24 Billion in 2008, representing approximately 15% of total healthcare spending.
As part of the Irish Governments cost reduction strategy under its National Recovery
Plan (2012-2013) the H.S.E. has been set very restrictive targets to reduce costs.
The widespread introduction of generic drugs is part of the H.S.E.’s policy to reduce
its expenditure.
The Irish Health Pricing and Supply of Medical Goods Bill 2012 was published in
July 2012 with enactment of the bill projected for the end of 2012. The bill promotes
“competition between suppliers of interchangeable or generic medicines and to
ensure value for money in the supply of medicines”, according to the explanatory
memorandum (Irish Government, 2012).

16

1.7 Environmental Costs
1.7.1 Carbon Footprint
The Carbon footprint is defined as the volume of carbon dioxide (C02) emitted into
the atmosphere by the activities of an individual, industry, location, etc. (Weidmann
et al, 2008). Climate change is becoming an increasingly important focus of the
political and corporate agenda; particularly as evidence linking global climate
change

to

carbon

emissions

becomes

increasingly

difficult

to

ignore

(Vezirgiannidou, 2008). Countries have responded politically to this evidence by
setting defined targets to reduce their carbon footprint. The Kyoto Protocol was
signed on 11 December 1997 in Japan and came into force in February 2005. It is a
binding international agreement that sets targets for 37 industrialized countries and
the European Union for reducing the volume of greenhouse gas emissions (Convery
et al, 2007). Coiporations have responded to global climate change by committing
to reduce carbon emissions associated with their respective activities. Changes such
as environmentally conscious packaging, greener chemistry and a reduction in
energy consumption per Kg of product produced have all been implemented and
continue to evolve (Schneider et al, 2010).
"We reduced emissions ofCOl-equivalents from our own facilities by S.SVo in 2011.
This includes energy and other production sources. Our main focus within our
facilities has been on energy efficiency activities where we have seen a 7.2%
decrease in C02-equivalent emissions. ”
GSK Corporate Responsibility Report 2011
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'‘Our GHG reduction program includes our voluntary and public commitment to
reduce GHG emissions and to use cleaner energy. We have reduced our GHG
emissions every year since 2000. Our current goal is to reduce C02 emissions by 20
percent on an absolute basis from 2008 through 2012 and we are on target to
achieve this. ”

Pfizer Annual Review 2011

“In 2009, M’e updated our carbon reduction target, pledging to reduce absolute
carbon dioxide emissions (from direct emissions or sources we owm or control and
from electricity we purchase) by 15 percent by 2015 compared with 2005 levels. By
the end of 2011, we had already reduced C()2e emissions, normalized by sales, by
17.5 percent. ”

Abbott Global Citizenship 2011

1.8 GlaxoSmithKline
GlaxoSmithKline is one of the world’s largest healthcare companies with annual
revenues of £27.4Billion (2011), consisting of £18.7Billion from pharmaceutical
sales, £3.5 Billion from Vaccines and £5.2 Billion from consumer healthcare -for a
list of the company’s leading products see Table 4. The company is headquartered in
Brentford, London and has approximately

100,000 employees worldwide.

GlaxoSmithKline spent £4.0Billion in 2011 on Research and Development, the
majority of which was on Pharmaceuticals-£3.16 Billion (GlaxoSmithKline, 2011).
Formed in 2000 by the merger of Glaxo Wellcome and Smithkline Beecham, the
company’s leading product in 2011 was Advair for Asthma therapy, with revenues
of £5.05 Billion in 2011.
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Table. 4. GlaxoSmithKline Leading Products
Modified from GSK annual report 2011

Vaccines

Consumer

Prescription

Ambirix

Horlicks

Tykerb

Cervarix

Gaviscon

Avandia

Hepatyrix

Lucozade

Paxil

Rotarix

Nicorette

Relenza

Varilrix

Aquafresh

Seroxat

Twinrix

Horlicks

Augmentin
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1.8.1 GlaxoSmithKline Cork

Figure 3. GlaxoSmithKline Production Facility at Cork (Research & Development
Pilot Plant Highlighted)

GlaxoSmithKline Ireland employs a total of over 1,400 people with facilities in
Dungarvan, Cork, Dublin and Sligo.
GlaxoSmithKline Cork was established in 1975 with the purpose of manufacturing
the active ingredients of pharmaceutical products. The site is based at Curabinny,
located in the inner harbour of Cork. GlaxoSmithKline has invested over €600
Million at the site since operations began, ensuring that the Cork Global
Manufacturing Site (G.M.S.) is up to world best standards, examples include
installing an innovative Nano Milling Facility, Research and Development Pilot
Plant (€34 Million) as well as upgrading all facilities. The Research and
20

Development Pilot Plant is a state of the art scale up facility, allowing researchers to
manufacture new products for clinical trials as well as identify issues with large scale
manufacturing should the products go to market.
Table. 5. Products manufactured at GlaxoSmithKline Cork
2011 Sales (£Million)

Product

Indication/Treatment

Paxil/Seroxat

Depression

435

Promacta/Revolad

Low platelet count

219

Requip

Parkinson's Disease

218

Tykerb

Breast Cancer

231

Adovart

Enlarged Prostate

748

Valtrex

Herpes Simplex Virus

339

Atriance

Leukaemia

New to market

21
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2.1 Materials and Methods
2.2 Introduction
The following section will explain the main energy users within the Research and
Development Pilot Plant, the formulas used to calculate costs as well as the project
implemented using software to reduce the annual energy costs.
The plant consumes energy in two main forms, electricity and Steam.
Electricity is used to drive pumps/motors, turn on lighting, produce Nitrogen via the
Pressure Swing Adsorption (PSA) plant etc.
Steam is used to heat reactor vessels via Dowtherm™ J, heat the building via the
Heating Ventilation and Air Conditioning System (HVAC) on the roof of the
building and sanitise purified water.
Each piece of equipment within the Research and Development Pilot Plant was
identified and its annual use calculated using the Distributed Control System (Delta
V). Delta V contains a software program. Process Explorer, which records data from
all the equipment within the Research and Development Pilot Plant. Process
Explorer is a Microsoft based Graphical User Interface (GUI) developed by
AspenTech, a Massachusetts Institute of Technology (MIT) project spinoff in
1981.Process Explorer is used to organise, display, and analyse real-time and
historical process data to workstations. Each piece of equipment has a unique
identifying tag, with individual components e.g. temperature transmitters also having
individual tags. Inputting the identifying tags and the required time frame enables the
annual usage for each piece of equipment to be determined using Process Explorer.
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Figure 4. Screenshot of Process Explorer showing vessel RV7503 temperaturesBaffle Temperature in green and Thermal Fluid (Dowtherm^'^ J) Supply Temperature
in red over 21 days (19 Nov to 30 Nov)

The electrical Current (I) used by each piece of electrical equipment running was
measured in real time by an electrician. This figure enabled the kilowatt per hour
(kW/h) figure to be calculated for each piece of equipment using the formula:
VxlxRoot3xCos0/lOOO= kW/h
The kilowatt per hour (kW/h) figure for each piece of equipment was multiplied by
the site electricity cost (€y per kWh). This figure represents the costs of each piece of
equipment per hour running. The annual usage (hours) was then used to calculate the
annual cost:
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kW/h X annual hours = total annual cost.

Steam cost and usage is calculated by identifying the Steam usage in each area via
Process Explorer. The financial cost to produce Steam per NP of natural gas via the
site boilers is known at GSK Cork (confidential).
2.3 Nitrogen
Nitrogen is heavily used within the chemical/pharmaceutical industries as a
blanketing gas. The use of highly flammable solvents within these industries requires
the use of Nitrogen as a safety precaution. The characteristics of Nitrogen (inert and
relatively cheap to isolate from Air) ensure that it is used as a replacement gas to Air,
thereby eliminating hazards associated with combustion.
2.3.1 Pressure Swing Adsorption- PSA
PSA is a technology used to separate gases. In industry it is utilised by isolating
Nitrogen from Air for use in processing.
The principal of Pressure Swing Adsorption can be divided into two phases;
•

Adsorption

•

Diffusion

Adsorption: Pressurised Air is passed through a Carbon Molecular Sieve made up
of Zeolites. Natural Zeolites are composed of hydrated alumina silicates, with micro
pores and channels typically 0.3 to 0.7 nanometres in diameter. Synthetic Zeloites
are generally used for commercial operations due to consistency and purity issues
with natural Zeolites. Nitrogen can be isolated due to the fact that Oxygen has a
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higher adsorption rate than Nitrogen at eertain pressures due to their slight difference
in molecular sizeOxygen (02) 0.28nmx0.40nm*

Nitrogen (N2) 0.30nmx0.41nm*

Nitrogen is isolated at the other end of the sieve in a receiver vessel, whilst the
Oxygen is collected on the sieve, as shown in Figure. 5.

. • , •• .*• •
AdlOfbor

CMS for

(H,)

Comprats»d
Air (N, & 0,>

Figure 5. Principle of Pressure Swing Adsorption Plant and Carbon Sieve
Pellets
Diffusion:

The vessel is then de-pressurised to desorb the low quality

Nitrogen/Oxygen mixture to a separate tank: the surge tank as shown in Figure 6.
(PSA plants work in tandem to ensure that whilst one side is collecting Nitrogen, the
other is desorbing the low Quality Nitrogen/Oxygen mixture).

"^approximate size depending, on method used to calculate size
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nmow^rw

Figure 6. PSA plant for Nitrogen

2.4 Thermal Oil-Dowtherm^'^'

The Dowtherm ^

range of heat transfer fluids are trademarks of the Dow chemieal

corporation. Dowtherm'*''^ is used as a heat transfer fluid to heat/cool vessels and
condensers within the chemical/pharmaeeutical industries.

Dowtherm""^
Jacket

Figure 7. Delta V screenshot of vessel RV7502 with Dowtherm™ jacket in yellow
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Dowtherms

advantages over traditional heating mediums such as Steam or glycol

include:

•

Wide Temperature Range (-50°C to 500°C) depending on grade

•

Non corrosive to metals

•

Low Viscosity

•

Good heat transfer characteristics

One disadvantage of using Dowtherm'^'^^ is the requirement to use a closed system,
due to the toxicity and volatile vapours of the product- Connections must be welded
on all pipe-work and any maintenance must be thoroughly planned to avoid exposing
Dowtherm^'^’ to the atmosphere.

DOWTHERM Synthetic Organic and
SYLTHERM Silicone Heat Transfer Fluids
T»nip»ra1u.<^o Range *C
-100

50

0

50 100 150 200 250 300 350 400

Liquid Phase
VApor Phase

DOWTHERM A

SYLTHERM 800

m

DOWTHERM G |

m

DOWTHERM RP
DOWTHERMQI
DOWTHERM J

Dowtherm

J

Liquid Phase
Vapor Phase

DOWTHERM HT
DOWTHERM T
SYLTHERM XLT^H
SYLTHERM HPHI
DOWTHERM MX
-100 0

100 200 300 400

600 600 700 800

Temperature Range *F

Figure 8. Dowtherm^'^ J Characteristics
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2.5 Three-Phase Motors
Electrical Motors are used extensively within the chemical/pharmaceutical industries
to power fans/pumps for the transfer of fluids. Motors in these industries use
Alternating Current (AC) as opposed to Direct Current (DC), which is most
commonly used within domestic buildings. The advantages of AC motors over their
DC equivalents are that they are less expensive to run, require less maintenance and
are better suited to high speed operations. As outlined in Figure 9 and Figure 10,
three-phase power has three arms carrying power, each arm is 120 degrees out of
phase with each other. Therefore when one arm is at the peak of its wave, another
arm is 2/3 near the bottom of its wave, and the third arm is 1/3 of the way towards
the crest of its wave therefore allowing the drive shaft within an electrical motor to
rotate.

Figure 9. Sine Waves & Principal of 3 Phase Alternating Current Electrical Motor
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Drive-shaft

Bearing

Figure 10. Cut-away View of a Three-Phase Induction Motor

2.6 Electrical Motors in Detail
Power [kW] = voltage [V] x current [Amp] x power-factor / 1000

As in domestic electricity bills, industry pays a certain price per watt hour -kilo watt
hour in the case of industry (kWh).
2.6.1 Voltage [V]
The electrical voltage used for Alternating Current in industry in Ireland in 380
volts. Offices and laboratories use Direct Current at 230 volts. Alternating Current is
used to power all large pieces of equipment - fans, pumps etc. on plant.
All large pieces of electrical equipment are required to have a faceplate stating basic
facts regarding the equipment as outlined in Figure 11.
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Amps Rating (at Full Load)
Voltage (U.S. Motor)

3 Phase

Horse Power

Power-Factor
[Cos

0]

_

Figure 11. Electric motor faceplate

2.6.2 Current [Amp]
The Amp rating (Current) states the maximum amount of Amps that the pump is
rated for. This is useful data when considering which pump to choose but does not
retlect the current a pump uses when running. Many pumps run at only a fraction of
their full capacity. Therefore for the purpose of accuracy, each “arm” of the three
phases of the AC motor when running at operational loads is measured. The three
readings (amps ) are averaged to give a true picture of the pumps electrical load.
2.6.3 Power-factor [Cos 0|
The power-factor of a motor is a correctional factor used to take account of
resistance due to bearings and the cooling fan within a motor ie. Real v’s Apparent
power of a motor. It is signified by a number eg. 0.85. This number is used in
calculations to account for resistance within a motor.
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2.6.4 Calculating Costs
Power [kW] = voltage [V] x current [Amp] x powerfactor/ 1000

Using the above factors it is possible to determine the actual power (kW) a motor
uses when running. The amount of hours a motor was running over a time period is
used to calculate the actual running costs for a motor (kWh).
Example for 1 kW motor running for 60 hours at a cost of 11 cents per kWh
60kWh X .lleuro = €6.60

2.7 Heat Exchanger
A heat exchanger is a piece of equipment which is used to efficiently transfer heat
from one medium to another. A boiler would be an example of a heat exchanger,
transferring heat from natural gas to water without any direct contact betw'een the
two mediums. In the context of this study the specific type of heat exchanger is a
plate heat exchanger. Thin metal plates are used to separate the two mediums and
can be adjusted by adding/subtracting plates as desired. Rubber gaskets ensure that
the two mediums are directed to each alternative space between plates as outlined in
Figure 12.
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Figure 12. Plate Heat Exchanger

2.8 Softv^are

2.8.1 GlaxoSmithKline Distributed Control System

A Distributed Control System (DCS) as illustrated in Figure 13, is a computerized
system (containing both hardware and software) used within a variety of industries,
to monitor and control distributed equipment. Distributed equipment includes
pumps, temperature probes, pressure transmitters, agitators, valves etc. Both input
and output modules form components of the DCS. The input modules receive
information from input instruments in the process “field” and transmit instructions to
the output instruments in the field.
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Figure 13. Overview of Distributed Control System Architecture

GlaxoSmithKine Cork uses the Emerson Delta V Distributed Control System to
control instruments/equipment “in the field”.

Personnel at GlaxoSmithKline Cork control the Delta V Distributed Control System
via workstations. The workstations present a graphical interface of the modules it
controls i.e. the R&D Pilot Plant workstations present a graphical interface of the
R&D Pilot Plant only. The workstations allow users to manipulate the
instruments/equipment within the associated module. Real time data and feedback is
presented on the workstation. Safety parameters are programmed into the software to
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prevent defined unsafe operations such as pressure values being set too high or
transferring solvents into a reactor that is not inert with Nitrogen.

B OHhiV Operate (Run)

Figure 14. Screenshot of Research and Development Pilot Plant Delta V user
interface.

2.8.1.1 Delta V Hardware
The Delta V hardware is designed in a modular format, allowing for the addition of
more complex and powerful hardware as required. Remote access, full automation of
a process, engineering modifications, investigational software etc. are all possible
with the addition of Emerson specific hardware modules. Operator interaction is via
a Delta V Workstation. The workstation displays interactive real-time information
fed from the Delta V Controller. The Delta V Controller collates all the data from the
input/output (I/O) Fieldbus’s and sends this information to the workstations, as well
as transmitting inputs from workstations to the equipment in the field. An I/O
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Fieldbus is a device which can read, store and transmit digital communications, such
as temperature and pressure values. The I/O Fieldbus gathers/sends information
directly from/to the equipment on plant. Foundation Fieldbus is the communication
protocol used to transmit the digital signals. It is a digital two-way communication
protocol.

Delta V Workstation

Input/Output

Delta V Controller

(l/0)"Field" Bus:
relaysinformation
to/from instruments
on plant

Figure 15. Delta V Hardware Overview
2.8.1.2 Delta V Software
Delta V uses a proprietary software system called “Delta V Predict Control Studio”
to; program instruments individually as control modules and then group them
together as equipment modules (EM). For example, the valves, agitators and
pressure/temperature transmitters etc on a reactor vessel will have their own control
module. An example of an equipment module is the Inerting EM where the control
modules for nitrogen inerting valves (high pressure/low pressure), the venting valves
(Incinerator, Vacuum) and the pressure transmitter are grouped to work together as a
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sequence that runs the inerting regime for that vessel. When the Inerting EM is asked
to either inert the vessel, set a certain vacuum or pressurise to a set point, the EM
controls the sequence and checks that correct pressures are achieved and maintained.
Safety interlocks, operational parameters, safe mode set-points etc. are all
programmed into the respective modules. The modules are created in Delta V
Control Studio using a user friendly system of software '‘blocks” as shown in Figure
16. The properties/ interlocks for the blocks are created using the control studio and
can be interconnected to create more complex software systems.
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Figure 16. Delta V Control Studio Software "Blocks" for Pump 402 and associated
Parameters

37

chapter III

38

3.1 Results*
3.2 Introduction

The R&D Pilot Plant has an annual energy bill in excess of €400,000. This energy is
consumed in many forms, from electricity to drive motors and pumps, gas
incineration to create Steam for heating vessels via Dowtherm'^^ J, to isolating
Nitrogen (N2) for use as an inert blanketing gas.

Figure 17. 3D Representation of GlaxoSmithKline Research and Development Pilot
Plant

^Due to commercial sensitivities only kWh (not specific financial costs) are shown.

39

Electrical energy is measured in kilowatt hours (kWh). The various pieces of
equipment within the plant which consume electricity were identified, the current
(A) they use when running measured by an electrician and the annual running hours
extrapolated from the R&D Pilot Plant Distributed Control System (Delta V). From
this data the annual running costs of each individual piece of equipment is
calculated.
Natural Gas is incinerated within the site boilers to create Steam from water. The
Steam usage for the R&D Pilot Plant is measured via flow-meters and using boiler
efficiency statistics the annual Natural Gas cost is calculated.

Overall R&D Energy Cost Breakdown
Electric Heater
0.4%
Jacket Recirc.

steam
27%

Pumps
11%

j ^
Pumps

Scrubbers and Area
Guard

2%

Figure 18. Overall R&D Energy Cost Breakdown
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3.3 Steam 27% of annual cost
Steam is used within the Pilot Plant to heat and cool vessels (via Dowtherm™ J),
sanitise purified water and also in the air conditioning units on the roof of the R&D
Pilot Plant. It is produced via two boilers:
Boiler 2701 bums natural gas to produce Steam called "expensive Steam” due to the
fact that natural gas is burned solely to produce Steam.
Boiler 2702 (waste heat boiler) is located within the thennal oxidiser housing. This
boiler produces Steam called "free Steam” as a by-product from heat generated from
the combustion of waste liquids and gases under strict environmental regulations and
monitoring.
3.4 HVAC 19% of annual cost
Heating and cooling a large building requires the expenditure of large amounts of
energy. Steam is used to heat the building, whilst fans driven by motors located on
the roof of the Pilot Plant are used to recirculate clean air throughout the building via
HHPA filters. Several large fans are used as different areas of the plant require
different volumes of clean air (Air Changes per Hour A.C.P.H.) dependent on the
functionality of each area.
3.5 Nitrogen 12% of annual cost
Nitrogen is used within the Pilot Plant to ensure all vessels are inert with a non
explosive gas. This is due to the flammability and explosion concerns regarding the
high usage of solvents and fine powders. The containment of Nitrogen is closely
monitored due to the inherent dangers associated with asphyxiation.
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3.6 Dowtherm^’'^ J Recirculation Pumps 11% of annual cost
The ten reactor vessels within the Pilot Plant have jackets through which
Dowtherm'^''^ J is recirculated. This ensures that each vessel has the capability to heat
and cool its contents through a wide range of temperatures. Dowtherm'^'^ J at -20°C
is heated by Steam to the desired temperature via a plate heat exchanger. Each vessel
has its own dedicated heating station and pump.

3.7 Lighting 8% of annual cost
The Pilot Plant at six storeys high requires a lot of lighting, both internally and
externally. All lighting within the Pilot Plant is EX rated (non explosive enclosures).
Various types of lighting are used within the Pilot Plant: process lighting, emergency
lighting, vessel lighting etc.
3.8 Vacuum pumps 7% of annual cost
T he four vacuum pumps within the Pilot Plant are used to create vacuum within the
reactor vessels, filter dryers and for sampling. The majority of products are dried
under vacuum, lowering the temperature at which solvents evaporate off.
Distillations and reflux’s within reactor vessels are performed regularly under
vacuum due to the high boiling point of some solvents; Pyridine-115°C, n-Butanol118°C.

3.9 Air 5% of annual cost
Air is used within the Pilot Plant in the following areas:
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Breathing Air: Purified Breathing Air is available to breathing hoods, whieh are
used when charging powders or solvents to vessels in conjunction with other safety
measures; local extraction fans etc.
Instrument Air: Instrument air is used to open and close the majority of valves within
the Pilot Plant. The valves are pneumatically controlled and are operated via the Pilot
Plant Distribute Control System.
3.10 Purified water 5% of annual cost
Purified water is used for the final stages of a products manufacture. It must be to the
highest standards of purity in accordance with the United States Pharmacopeia. The
process of producing water of this standard, free from contaminants and microbial
growth requires several separate operations; reverse osmosis, ultra filtration, and
Ultraviolet light sanitisation. The water must also be recirculated continuously and
sanitised weekly to reduce the opportunity for microbial growth occurring. Steam is
used to sanitise the water and a pump recirculates the water around a purified water
distribution loop.
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3.11 Detailed Analysis: Dowtherm^''^ J Recirculation Pumps/Steam
Steam is the largest contributor to energy costs within the Pilot Plant; therefore it
was decided to prioritise this utility for the energy cost reduction program. Steam is
used within three distinct areas of the Pilot Plant:

•

HVAC

An automated valve was installed to shut off Steam to the HVAC system at exterior
temperatures above 16°C, eliminating Steam utilisation to heat the Pilot Plant when
not required.

•

Purified Water

Purified water is sanitised weekly, using Steam via heat exchangers to heat the water
to above 80°C. The energy required to heat 3000 litres of water to 80°C is
significant. After discussions with the site microbiologist and quality department it
was decided to drain the purified water loop and holding tank wTen purified water is
not required for extended periods (greater than 10 days). Fresh w'ater would be
purified and sanitised three days prior to production requirements.

•

Dowtherm^'^ J Recirculation Skids

There are ten reactor vessels within the Pilot Plant which utilise Dowtherm^'^ J for
heating and cooling. Each vessel has its own dedicated heating/cooling skid,
consisting of a pump, heat exchanger, piping and associated valves. The
Dowtherm'^'^ J skids utilise Steam for heating and electricity for running the
recirculation pump. The Dowtherm’’^'^ J recirculation pump should not be running if
the vessel is empty and not in use. A detailed examination (below) was undertaken to
calculate:
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•

The percentage of time the Dowtherm'^'^ J recirculation pumps were
running when not required.

•

The energy and financial costs associated with the annual running of
the Dowtherm™ J Recirculation Skids

Figure 19 A. Reactor Vessel Dowtherm^"" J skid
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RV7502TC.grf

Figure 19 B. Delta V display of Reactor Vessel Dowtherm^'^ J skid

3.12 Dowtherm^'^^ J Recirculation Pumps/Steam Results

Figure 20. Explanation of Energy calculation tables for 10 R&D reactor Vessels
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Table 5. Dowtherm^'^ J Reactor Skids Analysis for 10 R&D Pilot Plant Reactor Vessels

RV7602

Vessel
Total Hrs running
2011

RV7603

8.8/9.9/9.7

Amps

VxlxRoot3xCos0/lOOO

kW Usage per Hour

8.1/9.7/9.4
VxlxRoot3xCos0/lOO
0
380x9.1x1.73X.88/10
00

2,528

2,536

380x9.5x1.73X.88/1000
5.50 kW/h
5.50x2,528=2011 kWh

5.26 kW/h
5.26x2,536=2011
kWh

2011 kWh

13,904 kWh

13,339.36 kWh

1,663 hrs running empty

1,359 hrs running empty

Vessel
Total Hrs running
2011

RV7504

7.0/7.9/7.6

Amps

VxlxRoot3xCos0/lOOO

kW Usage per Hour

5.4/8.0/7.5
VxlxRoot3xCos0/lOO
0

RV7601
3,631

8,273

380x7.5x1.73X.89/1000

380x7x1.73X.89/1000

4.39 kW/h
4.39x3,631=15,940.1
kWh

4.09 kW/h
4.09x8,273=2011
kWh

2011 kWh

15,940.1 kWh

33,836.57 kWh

2,206 hrs running empty

4683 hrs running empty

V7601/2

Vessel
Total Hrs running
2011

RV7604

7.9/7.7/7.5

Amps

VxlxRoot3xCos0/lOOO

kW Usage per Hour

9.0/9.7/9.4
VxlxRoot3xCos0/lOO
0
380x9.4x1.73X.88/10
00

3,676

4,036

380x7.7x1.73X.89/1000

5.44 kW/h
5.44x4,036=2011
kWh

4.51 kW/h
4.51x3,676=2011 kWh

2011 kWh

21,955.84 kWh
673 hrs running
empty

16,578.76 kWh
1,752 hrs running empty
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Vessel
Total Hrs running
2011
Amps
kW Usage per Hour

2011 kWh

Vessel
Total Hrs running
2011
Amps
kW Usage per Hour

2011 kWh

Vessel
Total Hrs running
2011
Amps
kW Usage per Hour

2011 kWh

V7501/2

Vessel
5,140

6.9/7.4/7.8
VxlxRoot3xCos0/lOOO

RV7501

Total Hrs running
2011

Vessel
3,642

Amps

7.5/8.4/7.5

Amps

kW Usage per Hour

VxlxRoot3xCos0/lOO
0

kW Usage per Hour

380x7.4x1.73X.89/1000

380x7.8x1.73X.85/10
00

4.33 kW/h

4.36 kW/h

4.33x5,140=2011 kWh

4.36x3,642=2011
kWh

2011 kWh

22,256.2 kWh

15,879.12 kWh

2,216 hrs running empty

1,948 hrs running empty

RV7502

Vessel
2,939

7.5/8.5/7.4
VxlxRoot3xCos0/lOOO

RV7503

Total Hrs running
2011

2011 kWh

Vessel
7,144

Total Hrs running
2011

Amps

7.5/8.4/7.5

Amps

kW Usage per Hour

VxlxRoot3xCos0/lOO
0

kW Usage per Hour

380x7.8x1.73X.85/1000

380x7.8x1.73x.85/10
00

4.36 kW/h

4.36 kW/h

4.36x2,939=2011 kWh

Total Hrs running
2011

4.36x7,144=2011
kWh

2011 kWh

1,2814.04 kWh

31,147.84 kWh

1,360 hrs running empty

5,279 hrs running empty
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2011 kWh

Graph 1. Analysis of R&D Vessel Dowtherm^'^ J Skids for 2011
R&D Vessel Dowtherm^^ Breakdown 2011 (Hours)
9000

Hours Running Full Vessel

Hours Running Empty Vessel

The data shows a total of 43,545 hours of the Reactor Vessel Dowtherm'^'^ J skids
running in 2011.
23,139 hours of this total involved the skids running when not necessary. The
parameters on Process Explorer used to determine if the vessels were in use were;
the agitator was running and the vessel level was greater than 20 litres. 23,139 hours
represents a 53.1% inefficiency of overall Dowlherm™ J skids usage, corresponding
to thousands of Euros in electricity and Steam wastage.
A solution to automate the shutdown of the respective Reactor Vessel Dowtherm'^'^ J
Skids when the vessels were empty was undertaken.
After several meetings the set-points to trigger Dowtherm’^'^ J skid shutdown for
each vessel were decided. Important factors such as safety and minimal impact on
processing were key considerations.
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The set-points were:
•

Vessel Agitator not running

•

Vessel Level greater than 20 litres

•

Vessel Temperature at 20°C +/- 2°C

If these conditions were met a ten minute timer would start. The timer would reset if
any of the set-points changed. Once 10 minutes elapsed, a pulse would be sent to the
Dowtherm'^''^ J skid automation to shut it down.
All of the set-points are user changeable to take account of scenarios out of the scope
of the automation- e.g. Toluene is radar absorbent causing no level reading to be
registered.

Table 6. Parameter set-points for automation of Reactor Vessel Dowtherm^*^ J skids

Component

Type

Format

Default

Description/Purpose

VESSEL_ENABLE

Input

Named
Set

DISABLED

Parameter
used
to
Automatic Stop control

VESSEL_TC

Input

Ext
Reference

N/A

Parameter used to report the status of the
vessel temperature control mode (Jacket,
Vessel, etc)

VESSEL_TC_STOP

Input

Named
Set

Stopped

Parameter used to compare the Jacket
service temperature control mode. Used
to check if the temperature control mode
is stopped.

VESSEL_TC_PV

Input

Ext
Reference

N/A

Parameter used to report the status of the
vessel
temperature
control
current
temperature.

VESSEL_TC_SP

Input

Floating
Point

20

Parameter used to compare the current
temperature of the vessel jacket service to
see if jacket control can be stopped.

VESSEL_DEADBAND

Input

Floating
Point

2

Parameter used as the dead-band
tolerance
allowed
for
the
vessel
temperature.
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Enable

Jacket

Component

Type

Format

Default

Description/Purpose

VESSEL_EMPTY

Input

Floating
Point

20

Parameter used to compare the current
level of the vessel to see if jacket control
can be stopped.

VESSEL_AGI

Input

Ext
Reference

N/A

Parameter used to report the status of the
vessel agitator.

VESSEL_DELAY

Input

Floating
Point

600

Parameter used for the time delay for all
permissive to be active before the jacket
service is stopped.

PULSE

Timed
Pulse

N/A

N/A

Timed Pulse used to trigger the jacket to
stop but only on a one shot and not
Latched.

VESSEL_STOP

Action
Block

N/A

N/A

Action Block used to set the Jacket Service
mode to Stopped.

VESSEL_MSG

Output

String

N/A

Parameter used to display status of
automatic jacket control to the operators
on the faceplate.
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Tuneable Parameters
which Dowtherm^“

10 minute timer
starts if preselected

Pulse sent to
Dowtherm"“ Skid to

Figure 21. Logic for automation of Reactor Vessel Dowtherm^"" J skids using Delta V
Control Studio
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4.1 Discussion
The purpose of this study was to identify the main factors contributing to the energy
consumption and associated costs at the Research and Development Pilot Plant at
GlaxoSmithKline, Cork. Such an undertaking required the identification and indepth examination of the various energy utilizing systems within the Research and
Development Pilot Plant. Once the various energy users were isolated and prioritised
according to annual energy usage, software changes to the Plant’s Distributed
Control System (DCS) were created and implemented to reduce the highlighted
inefficiencies.
The MSc in Computational Biology course equipped me with the skills required to
effectively lead this project, which relied on expertise at the interface between
Chemical Engineers and Software Engineers. The results demonstrate that by a
combination of careful planning and implementing a systematic approach, it is
possible to interpret very large amounts of data, extract key findings and apply
solutions to tackle highlighted inefficiencies.
1'he various energy streams were isolated and examined using pre-existing software.
Aspen Process Explorer, built into the Research and Development Pilot Plant DCS
software. The running costs for each equipment group, i.e. HVAC fans. Pumps and
their energy source(s), i.e. Electrical or Steam/Natural Gas, were calculated during
the 2011 calendar year, using internal GlaxoSmithKline Cork energy costs
i.e.€/kWh, combined with annual energy usage.
Due to high annual energy costs; the majority of large pharmaceutical companies
have put in place dedicated personnel, “Energy Champions”, to address their energy
costs on a full time basis. The GlaxoSmithKline Energy Champion and the Eli Lilly
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Energy Champion were both consulted early in the planning stage of this project to
help steer the research in the right direction.

The International Energy Management Standard, IS EN/6001, served as the template
for the project. IS EN/6001 is primarily composed of three key stages. The first stage
is to identify the current energy usage and where it is being used. The second stage
involves identifying opportunities for improvement, and what resources are required
to implement change. The third step involves scheduling a program to ensure that all
potential benefits identified are realised.
The overall energy results were very interesting. I'he electrical heater, at 0.4% of
annual energy costs, was expected to be a large contributor to energy use, due to the
fact that electricity is an inefficient and expensive means of heating, indeed based on
this, Sweden and Denmark have phased out the use of direct electric heating of
homes since 1980. According to Galitsky, (2008) the HVAC system is typically the
largest consumer of energy within Pharmaceutical Plants. At 19% of the 2011
Research and Development Pilot Plants energy use, HVAC is a very large user of
energy but not the largest.

The results show that at 27%, Steam is the major contributor to the Research and
Developments Pilot Plants annual energy costs for 201 l.This figure only takes into
account the cost of "expensive Steam” which makes up 46.3% of the total building
Steam usage. The actual usage of Steam within the plant is over twice the published
cost, but since the installation of the waste heat boiler in the site thermal oxidiser
producing "free Steam ”, Steam costs have virtually halved. Over 90% of the Steam
used within the Research and Development Pilot Plants was used to heat Reactor
Vessels via heating skids using Dowtherm™ J as the heating medium.
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This figure of 27% was unexpectedly high, Steam had been believed to be cheap and
plentiful, as well as the fact that it operates in the “background”. The heating of
Reactor Vessels, whilst common, was not directly associated with Steam usage and
the associated costs.
Careful analysis of the data not only identified Steam as the largest consumer of
energy but highlighted where it was being used inefficiently. HVAC operations and
purified water sanitisations accounted for less than 10% of the total R&D Pilot Plant
Steam usage, leaving the heating of reactor vessels, via Dowtherm'^*'^ J, as the key
activity to be addressed.
The implementation of the software solution for the DowthernA'^ J Heating Skids
was both challenging and time consuming. Several factors had to be considered for
the software solution to be successful, the most important being safety and avoiding
inadvertently obstructing processing operations. Meetings were held with all
stakeholders to the project, and a consensus reached which kept all parties satisfied.
Safety considerations, production issues, software integration and staff training were
all key elements which had to be addressed. For example; the software timer was
extended to ten minutes from five minutes due to concerns regarding the
Dowtherm'^'^ J Skids inactivation interfering with processing requirements. Also, a
“disable” button on the Graphical user Interface (GUI) was built into the software to
allow it to be disabled in situations where heating and cooling of Reactor Vessels
was critical to safety.
The software changes to Delta V, the GlaxoSmithKline DCS; regarding the
Dowtherm^'^ J Reactor heating skids, is primarily composed of three pre-conditions
which must be met in order to shut down the Dowtherm'^'^ J heating skid.
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The first condition is that the Reactor Vessel must be empty.

The second is that the Reactor Vessel agitator is not running.

The third condition is that the Reactor Vessel temperature is at 20°C +/- 2°C.
If these three conditions are met a timer runs for 10 minutes. When the allotted time
elapses a pulse is sent to the Dowlherm

heating skid to shut it down. The

software was developed using Delta V Control Studio, a program used specifically to
manipulate Delta V.
The success of the project was recognised by the awarding of a Global Recognition
Award from GlaxoSmithKline (scanned award attached in Appendices section). The
project is currently being implemented; the software has been uploaded onto the
R&D Pilot Plant DCS servers and will go live on a vessel by vessel basis as the
reactor vessels become free. Training of relevant personnel on the upgrade is also
planned in tandem with the system going live. Calculations of potential savings for
2011 arising from the software implementation work out at nearly €20,000. Phis
figure will invariably change on a monthly basis depending on the processing
requirements within the R&D Pilot Plant.
Planned future improvements include software to turn off the two Filter Dryer
Vacuum Pumps when they are not required i.e. data shows that the vacuum pumps
are costing several thousand Euro's to run per annum and yet are required for drying
product for less than 30% of 2011. The software change will be similar to the
Dowtherm'^'^ J software project, with a set of pre-conditions required to be met
before a pulse is sent to shut down the Filter Dryer Vacuum Pumps.
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The GSK Research and Development Pilot Plant at Cork is only one of over ten
production buildings within the Cork site. This project served as a pilot for the
implementation of similar projects within the other production buildings. The
software tools to investigate energy inefficiencies are readily available on site.
This project is only one facet of the GlaxoSmithKline strategy, both locally and
globally, to reduce financial and environmental costs.
GlaxoSmithKline has set stringent targets regarding its future Carbon Dioxide (CO2)
emissions. The corporation’s aim is to be “Carbon Neutral” regarding all processing
activities by 2050 (GlaxoSmithKline Corporate Responsibility Report 2011).
GlaxoSmithKline Cork is aggressively addressing these underlying energy issues.
On the 3"^^ of December 2012, GlaxoSmithKline Cork announced that ''An Bard
Plecmala has approved planning permission for the erection of a lOOm wind turbine
plus blade radius of 50.5m (total height from ground to blade tip of 150.5m)

fhe

wind turbine is expected to be operational by August 2014 and requires the
investment of several million Euros. This project will help GlaxoSmithKline Cork to
reduce its energy costs by up to 30% as well as a helping to reduce its carbon
footprint by up to 22,000 tonnes per year.
GlaxoSmithKline Cork has also created a new group called “2"^ Generation” which
are investigating greener chemistry and reducing the complexity of chemical
reactions for existing and new products.
It is only by integrating projects on a small scale i.e. R&D Pilot Plant Project, large
scale i.e. Wind Turbine Project and globally i.e. “2*^^ Generation” that
GlaxoSmithKline will achieve its commitments to Global Climate Change
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